INDGENE: GERMAN SUBSIDIARY MERGER COMPLETE

• Indegene Healthcare Germany GmbH merged with Trilogy Writing & Consulting GmbH, both indirect wholly owned subsidiaries in Germany. • The merger was registered with the Commercial Register of the Local Court of Frankfurt am Main on September 9, 2026, becoming effective on the same date. • Indegene Healthcare Germany GmbH ceased to exist, with Trilogy Writing & Consulting GmbH becoming the surviving entity. • The surviving entity subsequently changed its name to Indegene Healthcare Germany GmbH. • Projected revenue of the surviving entity for FY 2026-27 is Euro 20,100,000. • The merger is part of an internal reorganization and has no material impact on business operations, shareholding pattern, or financial position. Impact: Neutral (Internal restructuring of subsidiaries with no material impact on parent financials or operations)

Indegene Limited

Open attachment

← Back to feed